Atezolizumab (Tecentriq®) accepted for use within NHS Scotland in combination with nab-paclitaxel for treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer

Approval based on RCT which showed addition of atezolizumab to nab-paclitaxel significantly improved progression-free survival in this group of patients who also had PD-L1 expression ≥1% and who had not received prior chemotherapy for metastatic disease.

Source:

Scottish Medicines Consortium